Statins can have both beneficial and detrimental effects on brain cells

Washington, Oct 29 : Apart from treating high cholesterol and lowering the risk of heart disease, statins have also been found to potentially reduce the risks of other diseases, such as dementia. But, a new study has shown that similar statin drugs can have profoundly different effects on brain cells – both beneficial and harmful.

These findings support the idea that great care should be taken when it comes to decision on the dosage and type of statin given to individuals, particularly the elderly.

For the study, John Albers and colleagues compared the effects of two commercially used statins, simvastatin and pravastatin, on two different types of brain cells, neurons and astrocytes (support cells that help repair damage).

By directly applying the drugs to cells as opposed to administering them to animals, they could eliminate differences in the drugs'''' ability to cross the blood-brain barrier as a reason for any differing effects.

The researchers looked at the expression of genes related to neurodegeneration, and found that indeed, despite using biologically equivalent drug concentrations, differences were seen both between cells, and between drugs; for example, simvastatin reduced the expression of the cholesterol transporter ABCA1 by approximately 80 percent in astrocytes, while pravastatin lowered expression by only around 50 percent.

Another interesting difference was that while both statins decreased expression of the Tau protein – associated with Alzheimer''''s disease—in astrocytes, they increased Tau expression in neurons; pravastatin also increased the expression of another Alzheimer''''s hallmark, amyloid precursor protein (APP).

While increased levels of these two proteins may account for potential risks of disease, the researchers also note that large decreases in cholesterol proteins like ABCA1 should be considered.

Brain cholesterol levels tend to be reduced in elderly people, and in such individuals the long-term effects of statin therapy could lead to transient or permanent cognitive impairment.

The study has been published in the October Journal of Lipid Research.

--ANI